Press Releases

The following are official statements issued by UsAgainstAlzheimer’s in response to major national policy actions, industry events, breaking news, or organizational achievements. Please see the UsAgainstAlzheimer’s press kit page for additional information. For media requests, please contact Roger Lowe at or 202.494.3051

  • June 21, 2021

    New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

    The FDA’s approval of Aduhelm is a breakthrough in the fight to...

    Read more
  • June 07, 2021

    UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

    "This first disease-slowing drug is a dramatic turning point in the fight...

    Read more
  • May 19, 2021

    UsAgainstAlzheimer’s Welcomes Bipartisan Introduction of CHANGE Act to Encourage Early Detection and Diagnosis of Alzheimer’s

    UsAgainstAlzheimer’s welcomed the bipartisan introduction today in Congress of the CHANGE Act...

    Read more
  • May 19, 2021

    Broad Range of Health, Aging, Consumer and Dementia Groups call for Congress to Triple Funding for CDC’s Alzheimer’s Disease and Healthy Aging Program

    More than 50 health, medical, aging, consumer, Alzheimer’s and dementia advocacy groups...

    Read more
  • May 05, 2021

    UsAgainstAlzheimer’s Says Draft Report on Value of Alzheimer’s Treatment will be Disappointing to Patients and Caregivers

    Patients and caregivers will be disappointed that this draft finding fails to...

    Read more
  • April 28, 2021

    UsAgainstAlzheimer’s and the Paid Leave Alliance for Dementia Caregivers Praises Biden Administration Proposal to Expand Paid Family and Medical Leave

    No one should have to choose between their job and their family’s...

    Read more
  • April 09, 2021

    UsAgainstAlzheimer’s Applauds Proposed Advanced Research Projects Agency for Health to Spur Federal Alzheimer’s Research

    UsAgainstAlzheimer’s issued the following statement applauding the Biden Administration proposal for a...

    Read more
  • April 05, 2021

    UsAgainstAlzheimer’s Statement on FDA Failure to Approve Acadia Drug for Treatment of Dementia-related Hallucinations and Delusions

    We are extremely frustrated and disappointed that the FDA has failed to...

    Read more
  • March 31, 2021

    UsAgainstAlzheimer’s Applauds Biden Administration Infrastructure Proposals for Public Health, Research and the Care Economy

    We applaud the Biden administration's commitment to building essential public health and...

    Read more

Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer's. This report found that deep social inequities exist in countries highly impacted by Alzheimer's among Latinos and Blacks.